— Disease indication – In combination with anti-PD-1 therapy for cancer. Anti-PD-1 therapy is currently approved for:
Drug format – Monoclonal antibody
Drug class – First-in-class
Target – TREM2
Research stage and preliminary data – The inventors performed initia…
— Technology Description
A team of researchers, led by Richard Hotchkiss at Washington University in St. Louis, have developed a version of the ELISpot assay to determine if COVID-19 patients are in a hyper-inflammatory or immunosuppressed state. The results of this assay, which can be performed wit…
— Technology Description
Researchers in Prof. Marco Colonna’s laboratory have identified a receptor-ligand interaction that could be harnessed to activate the innate immune system to treat cancer or enhance the response to vaccines for infectious disease. Specifically, platelet-derived growth f…
— Disease indication – SARS-CoV-2 infection (COVID-19)
Drug format – Chimeric monoclonal antibody
Drug class – Best-in-class
Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…
— Technology Description:
Researchers in the lab of Emil Unanue at Washington University have discovered a panel of peptides responsible for autoimmune activation in Type 1 diabetes and potentially capable of diagnosing T1D at an early stage. These peptide fragments of insulin are found circulating …
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
